Pharmacology
News
Limiting antibiotic overprescription in pandemics: New guidelines
The COVID-19 pandemic brought an alarming increase in antimicrobial resistance in hospitals, with infections and deaths caused by resistant...
News
FDA okays terlipressin (Terlivaz) injection for hepatorenal syndrome
The synthetic vasopressin analog is an injectable medication indicated for patients with hepatorenal syndrome experiencing rapid deterioration of...
News
Ketamine linked to reduced suicidal thoughts, depression, anxiety
Sex, age, and other demographic characteristics did not predict response or remission, but suicide planning trended toward higher response rates...
Conference Coverage
Is acetaminophen really safer than NSAIDs in heart disease?
A new analysis finds a significant correlation between acetaminophen use and elevated systolic blood pressure.
Conference Coverage
‘Game changer’ semaglutide halves diabetes risk from obesity
Post-hoc analysis of two semaglutide trials in people with obesity showed treatment cut their projected 10-year risk for incident type 2 diabetes...
Latest News
Adderall shortage reported by pharmacies, patients
Patients have been told the drug would not be available for weeks, though it’s supposed to be taken daily.
Latest News
Atezolizumab doubles survival of NSCLC patients with poor performance status
Patients typically excluded from clinical trials because of age or comorbidities had better survival with atezolizumab than single-agent...
Latest News
Brodalumab suicide risk similar to other biologics, postmarket study finds
The researchers extracted data through the end of 2021 on the number of completed suicides for brodalumab and ten other biologics approved for...
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
News
BRAF/MEK combo shows long-term efficacy in melanoma
Despite positive results, immunotherapy likely remains the best choice for first-line treatment of BRAFV600 mutated advanced melanoma.